FI971784A0 - Apolipoproteiini B-synteesin estäjiä - Google Patents

Apolipoproteiini B-synteesin estäjiä

Info

Publication number
FI971784A0
FI971784A0 FI971784A FI971784A FI971784A0 FI 971784 A0 FI971784 A0 FI 971784A0 FI 971784 A FI971784 A FI 971784A FI 971784 A FI971784 A FI 971784A FI 971784 A0 FI971784 A0 FI 971784A0
Authority
FI
Finland
Prior art keywords
apolipoprotein
synthesis inhibitors
inhibitors
synthesis
Prior art date
Application number
FI971784A
Other languages
English (en)
Swedish (sv)
Other versions
FI971784A (fi
FI119548B (fi
Inventor
Jan Heeres
Leo Jacobus Jozef Backx
Robert Jozef Maria Hendrickx
Der Eycken Luc Alfons Leo Van
Chaffoy De Courcelles Didie De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/455,304 external-priority patent/US5521186A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI971784A0 publication Critical patent/FI971784A0/fi
Publication of FI971784A publication Critical patent/FI971784A/fi
Application granted granted Critical
Publication of FI119548B publication Critical patent/FI119548B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI971784A 1994-10-27 1997-04-25 Apolipoproteiini B-synteesin estäjiä FI119548B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP94203120 1994-10-27
EP94203120 1994-10-27
US08/455,304 US5521186A (en) 1994-10-27 1995-05-31 Apolipoprotein-β synthesis inhibitors
US45530495 1995-05-31
EP9504111 1995-10-19
PCT/EP1995/004111 WO1996013499A1 (en) 1994-10-27 1995-10-19 Apolipoprotein-b synthesis inhibitors

Publications (3)

Publication Number Publication Date
FI971784A0 true FI971784A0 (fi) 1997-04-25
FI971784A FI971784A (fi) 1997-04-25
FI119548B FI119548B (fi) 2008-12-31

Family

ID=26136684

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971784A FI119548B (fi) 1994-10-27 1997-04-25 Apolipoproteiini B-synteesin estäjiä

Country Status (30)

Country Link
US (1) US5929075A (fi)
EP (1) EP0788496B1 (fi)
JP (1) JP3025907B2 (fi)
KR (1) KR100227231B1 (fi)
CN (1) CN1068000C (fi)
AP (1) AP779A (fi)
AT (1) ATE198889T1 (fi)
AU (1) AU697744C (fi)
BG (1) BG63694B1 (fi)
BR (1) BR9509436A (fi)
CA (1) CA2203274C (fi)
CY (1) CY2256B1 (fi)
CZ (1) CZ286476B6 (fi)
DE (3) DE122007000005I1 (fi)
DK (1) DK0788496T3 (fi)
ES (1) ES2155535T3 (fi)
FI (1) FI119548B (fi)
GR (1) GR3035519T3 (fi)
HR (1) HRP950532B1 (fi)
HU (1) HU219862B (fi)
IL (1) IL115771A (fi)
LU (1) LU91306I2 (fi)
NO (1) NO311937B1 (fi)
NZ (1) NZ295353A (fi)
OA (1) OA10479A (fi)
PT (1) PT788496E (fi)
RO (1) RO118715B1 (fi)
SK (1) SK281908B6 (fi)
TR (1) TR199501295A2 (fi)
WO (1) WO1996013499A1 (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1028730B1 (en) * 1997-11-03 2002-04-17 Janssen Pharmaceutica N.V. Compositions of lipid lowering agents
SK15252000A3 (sk) * 1998-04-27 2001-10-08 Janssen Pharmaceutica N. V. Peleta, ktorej jadro je obalené činidlom znižujúcim lipidy a polymérom
US6451802B1 (en) * 1998-12-22 2002-09-17 Janssen Pharmaceutica N.V. S-oxide lipid lowering compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US20050132022A1 (en) * 2003-12-12 2005-06-16 International Business Machines Corporation Computer system with LAN-based I/O
EP1708680A2 (en) * 2004-01-21 2006-10-11 Janssen Pharmaceutica N.V. Mitratapide oral solution
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
WO2005097131A2 (en) * 2004-04-09 2005-10-20 Janssen Pharmaceutica N.V. Intermittent dosing regimen for the treatment of overweight with mtp-inhibitors
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US20080269233A1 (en) * 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
RS20080371A (en) * 2006-02-23 2009-07-15 Pfizer Limited, Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008059335A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
ATE474836T1 (de) * 2007-05-25 2010-08-15 Janssen Pharmaceutica Nv Verbesserte synthese von (2s-cis)-2-(brommethyl)- 2-(4-chlorphenyl)-1,3-dioxolan-4-methanol- methansulfonat(ester)
MX2011001405A (es) * 2008-08-06 2011-03-21 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de mc4.
EP2571871B1 (en) * 2010-05-19 2017-06-21 Sandoz AG Process for the preparation of chiral triazolones
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4313953A (en) * 1978-06-23 1982-02-02 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
WO1994020063A2 (en) * 1993-03-04 1994-09-15 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
MX9703074A (es) 1997-07-31
SK281908B6 (sk) 2001-09-11
DE122007000005I2 (de) 2008-04-24
AU3868095A (en) 1996-05-23
ATE198889T1 (de) 2001-02-15
NZ295353A (en) 1998-08-26
HRP950532B1 (en) 2001-06-30
KR100227231B1 (ko) 1999-11-01
CZ286476B6 (en) 2000-04-12
IL115771A (en) 2000-02-29
OA10479A (en) 2002-04-09
AP9700968A0 (en) 1997-04-30
NO971895L (no) 1997-04-24
AP779A (en) 1999-11-03
JPH09511759A (ja) 1997-11-25
TR199501295A2 (tr) 1996-06-21
NO311937B1 (no) 2002-02-18
WO1996013499A1 (en) 1996-05-09
RO118715B1 (ro) 2003-09-30
DE122007000005I1 (de) 2007-04-26
HRP950532A2 (en) 1997-08-31
GR3035519T3 (en) 2001-06-29
CA2203274A1 (en) 1996-05-09
CN1068000C (zh) 2001-07-04
SK50797A3 (en) 1998-04-08
AU697744B2 (en) 1998-10-15
CY2256B1 (en) 2003-07-04
CZ119897A3 (cs) 1998-03-18
HU219862B (hu) 2001-08-28
AU697744C (en) 2002-08-22
CA2203274C (en) 2002-02-19
BR9509436A (pt) 1998-01-06
BG101402A (en) 1997-10-31
DE69519995D1 (en) 2001-03-01
ES2155535T3 (es) 2001-05-16
IL115771A0 (en) 1996-01-19
EP0788496B1 (en) 2001-01-24
FI971784A (fi) 1997-04-25
EP0788496A1 (en) 1997-08-13
DE69519995T2 (de) 2001-08-23
HUT77360A (hu) 1998-03-30
US5929075A (en) 1999-07-27
JP3025907B2 (ja) 2000-03-27
FI119548B (fi) 2008-12-31
BG63694B1 (bg) 2002-09-30
CN1161695A (zh) 1997-10-08
DK0788496T3 (da) 2001-06-18
PT788496E (pt) 2001-07-31
LU91306I2 (fr) 2007-03-19
NO971895D0 (no) 1997-04-24

Similar Documents

Publication Publication Date Title
FI963597A (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
FI972160A (fi) Matriisimetalloproteaasi-inhibiittorit
FI971784A0 (fi) Apolipoproteiini B-synteesin estäjiä
NO942064D0 (no) yminhibitorer
DE69736445D1 (de) Refluxinhibitoren
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
ATE230275T1 (de) Angiogense-inhibitor
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
EE9700093A (et) Apolipoproteiin-B sünteesi inhiibitorid
DE69736109D1 (de) Differenzierungsinhibitor
FI971156A (fi) 5alfa-reduktaasi-inhibiittoreita
DE69523450T2 (de) Inhibitor
DE69720957T2 (de) Ace-hemmer
BR9610514A (pt) Inibidores cicloantihelmínticos
CY2007006I1 (el) Αναστολεις συνθεσης απολιποπρωτεινης-β
FI1878U1 (fi) Maskmetspoe utan floete
FI943697A0 (fi) Riktningventil utan roera delar
KR970703937A (ko) 금속단백질 분해효소 억제제(Metallproteinase inhibitors)
FI941265A (fi) Heterosyklisiä sulfoniamidotrombiini-inhibiittoreita

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Free format text: SPC C20090011

Spc suppl protection certif: C20090011

PC Transfer of assignment of patent

Owner name: ELANCO ANIMAL HEALTH IRELAND LIMITED

Free format text: ELANCO ANIMAL HEALTH IRELAND LIMITED

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 358

Extension date: 20201019

MM Patent lapsed